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Investigation of sphingosine kinase 1 in interferon
responses during dengue virus infection
Amanda L Aloia1,4, Julie K Calvert1, Jennifer N Clarke1, Lorena T Davies2, Karla J Helbig3, Stuart M Pitson2
and Jillian M Carr1
Dengue virus (DENV) regulates sphingosine kinase (SK)-1 activity and chemical inhibition of SK1 reduces DENV infection. In
primary murine embryonic fibroblasts (pMEFs) lacking SK1 however, DENV infection is enhanced and this is associated with
induction of normal levels of interferon beta (IFN-β) but reduced levels of IFN-stimulated genes (ISGs). We have further
investigated this link between SK1 and type I IFN responses. DENV infection downregulates cell-surface IFN-alpha receptor
(IFNAR)1 in both wild-type (WT) and SK1−/− pMEF, but, consistent with poor ISG responses, shows reduced induction of
phosphorylated (p)-STAT1 and key IFN regulatory factors (IRF)1 and −7 in SK1− /− pMEF. Direct IFN stimulation induced ISGs
(viperin, IFIT1), CXCL10, IRF1 and −7 and p-STAT1. Responses, however, were significantly reduced in SK1− /− pMEF, except
for IFN-stimulated CXCL10 and IRF7. Poor IFN responses in SK1− /− pMEF were associated with a small reduction in basal
cell-surface IFNAR1 and IRF1 mRNA in uninfected SK1− /− compared with WT pMEF. In contrast, treatment of cells with the
SK1 inhibitor, SK1-I or expression of an inhibitory SK1 short hairpin RNA (shRNA), both of which reduce DENV infection, does
not alter basal IRF1 mRNA or affect type I IFN stimulation of p-STAT1. Thus, cells genetically lacking SK1 can induce many
responses normally following DENV infection, but have adaptive changes in IFNAR1 and IRF1 that compromise DENV-induced
type I IFN responses. This suggests a biological link between SK1 and IFN-stimulated pathways. Other approaches to reduce
SK1 activity, however, do not influence these important antiviral pathways but reduce infection and may be useful antiviral
strategies.
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Dengue virus (DENV) is a positive-strand RNA virus of the flavivirus
family that is estimated to infect around 100 million people each year,
resulting in ~ 500 000 hospitalisations and 25 000 deaths.1 With the
geographic range of the mosquitoes responsible for spreading DENV
increasing, DENV infections are likely to increase.2 A new DENV
vaccine has recently been licenced in some countries but no direct-
acting antiviral treatments are available. The progression of DENV
disease has been suggested to be an immunopathogenesis, whereby the
immune system is dysregulated. Thus, there has been much focus on
the roles of innate and interferon (IFN)-driven responses during
DENV infection3–5 and the association of this with the induction of a
pathogenic cytokine response.6–8
In vivo, DENV replication primarily occurs in monocytes, macro-
phages and dendritic cells.9,10 Following infection DENV RNA is
detected by pattern recognition receptors such as toll-like receptors
and retinoic acid-inducible gene 1 (RIG-I).5,11 This subsequently
elicits an antiviral response via pathways initiated by intracellular
factors including IFN regulatory factors (IRFs). These IRFs have an
important role in stimulating transcription and production of factors
such as IFNs, tumour necrosis factor-α (TNF-α) and interleukins. The
major ‘canonical’ type I IFN pathway is stimulated by IFN-α/β binding
to a heterodimeric complex of IFN-α/β receptor (IFNAR)-1 and
IFNAR212 and subsequently activating JAK/signal transducer and
activator of transcription (STAT)-1 and STAT2 by a cascade of
phosphorylation events. Phosphorylated STAT1 and STAT2 interact
with IRF9 to form the ISGF3 complex that binds to IFN-sensitive
response elements in IFN-stimulated genes (ISGs) such as key
antivirals: viperin and IFN Induced Protein With Tetratricopeptide
Repeats 1 (IFIT1), and also IRFs themselves, thus creating a positive
feedback loop between IRFs, IFN and ISGs.13,14 IRF3 and IRF7 are
traditionally thought to respond to RNA viruses and IRF7 has been
demonstrated to have a role in protective responses against DENV
infection.15 While these are generalities in cellular responses to viral
infection, the induction of these antiviral responses are coordinated
and distinctly regulated by a growing number of complex interacting
pathways.
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One new cellular factor that we have identified to influence the IFN
response that is induced following DENV infection is sphingosine
kinase1 (SK1). SK1 is the major isoform of SK in most cells and tissues
and functions in the sphingolipid metabolic pathway to convert
sphingosine to sphingosine-1-phosphate (S1P).16,17 S1P can function
intracellularly and can also be exported extracellularly to act via a
family of five G-protein-coupled receptors (S1PR1–5) to elicit growth
promoting and immunomodulatory functions.16–19 A few studies have
linked the SK1/S1P axis to intracellular cytokine signalling pathways.
Work from our laboratory and others have shown that TNF-α
stimulation has reduced capacity to activate NFκB when SK1 is absent
or reduced.20–22 Later work by others has described an association of
SK1/S1P with TNF receptor-associated factor 2 to activate nuclear
factor κB (NFκB) following TNF-α stimulation.23 More recently
however, this has been questioned with SK1 deemed not essential
for TNF-α-induced activation of NFκB and inflammatory responses
in keratinocytes24 or macrophages.25 In addition, interleukin-1-
stimulated and IRF1-mediated induction of CXCL10 and CCL5
requires phosphorylated SK1 that complexes with TNF receptor-
associated factor 6, S1P and cIAP2 to promote IRF1 ubiquitination.
The ubiquitinated IRF1 can be activated by phosphorylation and can
translocate to the nucleus to interact with NFκB and induce CXCL10
and CCL5 expression.26
In response to infection, overexpression of SK1 reduces the capacity
of influenza A virus (IAV) to induce p-STAT1, and these authors have
proposed a role for SK1 in negatively regulating IFN signalling.27,28
Our previous work has defined changes in SK1 activity during DENV
infection20,29 but discrepant effects of modulating SK1 on DENV
infection; overexpression of SK1 has no effect, chemical inhibition of
SK1 or infection of an immortalised SK1− /− murine embryonic
fibroblast line reduces infection, but infection of multiple isolates of
SK1− /− primary (p)MEF are enhanced.30 Studying the induction of
ISGs is confounded in models such as immortalised SK1− /− murine
embryonic fibroblast and SK1 drug inhibition, since DENV replication
is concurrently reduced. In the latter SK1− /− primary murine
embryonic fibroblast (pMEF) model, however, we observed reduced
mRNA levels of the ISGs IFIT1, viperin and the ISG chemokine
CXCL10 following DENV infection, despite higher replication and
normal-higher IFN-β levels than wild-type (WT) pMEF.30 This
implies that a lack of SK1 affects events post-IFN-β production
and/or IFN-β-independent pathways that culminate in the induction
of IFIT1, viperin and CXCL10 in response to DENV infection.
Here we have further defined the responses of cells with reduced
SK1 to DENV infection and type I IFN stimulation. We show that cells
genetically lacking SK1 show some elements of normal responses to
DENV infection but have reduced ability to induce key ISGs following
DENV infection or IFN-β stimulation. This is associated with a small
decrease in uninfected cells of cell-surface IFNAR1 and IRF1 (mRNA)
—both major mediators and enhancers of ISG expression—as well as
reduced ability to induce Y701-p-STAT1—an important post-receptor
signalling pathway for type I IFN activation of ISGs. These changes in
basal IRF1 and p-STAT1 are not evident in uninfected cells treated
either chemically or with a short hairpin RNA (shRNA) to reduce SK1.
Our results suggest that the difference in ability of DENV to infect cells
lacking SK1 (SK1− /−), where infection is enhanced, compared with
cells with reduced SK1 (SK1-I; SK1 shRNA), where infection is
reduced, is likely due to adaptive changes in key components of
the IFN response in SK1− /− cells. These findings have important
implications for interpretation of genetic manipulations of SK1 in
relation to IFN and antiviral responses and the potential for use of SK1
inhibitors as therapeutics in an infectious setting.
RESULTS
Some responses to DENV infection are similar in both WT and
SK1− /− MEF, but induction of key IFN responses are reduced in
SK1− /− pMEF
Our prior data have suggested that the induction of ISGs are reduced
in DENV-infected SK1− /− pMEF,30 so to assess the type I IFN
signalling pathways in SK1− /− pMEF following DENV infection we
measured IFNAR1 protein by flow cytometry and IFNAR2 mRNA
by reverse transcriptase polymerase chain reaction (RT-PCR).
Cell-surface IFNAR1 was significantly reduced at 24 h pi in both
DENV-infected WT and SK1− /− pMEF (Figures 1a and b). In
contrast, at the mRNA level, IFNAR2 was significantly induced
following DENV infection, but was not significantly different in WT
compared to SK1− /− pMEF (Figure 1c). This demonstrates similar
Figure 1 Cell-surface IFNAR1 is reduced and IFNAR2 mRNA is increased in
both DENV-infected WT and SK1− /− pMEF. WT and SK1− /− pMEF were left
uninfected or infected with DENV, as indicated directly on figures. (a) At
24 h pi cells were harvested and stained using APC-conjugated IFNAR1 or
isotype control antibodies. Cells were fixed and subjected to flow cytometry.
Representative histograms are shown; (b) as in a with av± s.e.m. of mean
florescent intensity (MFI) from replicate (n=3) flow analysis from n=2
independent pMEF preparations; (c) RNA was extracted at the indicated
time point pi and subjected to RT-PCR for IFNAR2. Results were normalised
against cellular cyclophilin and relative RNA level determined by ΔCt
method. Data represent av± s.e.m. from n=2 RT-PCR values from n=3
independent pMEF preparations and infection experiments. Representative
replication profile of infectious DENV release is shown in Figure 2a.
*Po0.05, Student's unpaired t-test.
Sphingosine kinase, interferon and dengue
AL Aloia et al
2
Clinical & Translational Immunology
responses of the type I IFN receptor to DENV infection in WT and
SK1− /− pMEF.
A major pathway for type I IFN signalling to induce ISGs is
activation of the JAK/STAT pathway, primarily by phosphorylation of
STAT1 on tyrosine 701 (Y701; p-STAT1). We next assessed the ability
to induce p-STAT1 following DENV infection. Productive DENV
infection was observed with 2–3 log increase in infectious virus release
compared with input virus at 2 h pi and, as observed previously,
a significant increase in virus release from SK1− /− pMEF at 48 h pi
(Figure 2a). Concurrent with this increase in infectious virus release,
DENV infection induced p-STAT1 in both WT and SK1− /− pMEF,
with a reproducible reduction in SK1− /− compared with WT pMEF
(Figures 2b and c). Total STAT1 increased at 48 h pi in both WT and
SK1− /− cells, as we have previously described in DENV-infected
endothelial cells.29 Total STAT1 levels tended to be lower in
uninfected SK1− /− compared with WT pMEF (see also Figure 3b),
although this signal was low and varied between donor MEF
preparations. Reliably, total STAT1 levels were increased in SK1− /−
compared with WT cells at 48 h pi (Figures 2b and c).
We have previously focused on IFIT1, viperin, CXCL10 and IRF7
mRNA changes following DENV infection,30 while there is prior
evidence for a linkage of SK1 with IRF1-mediated CXCL10
induction.26 Therefore, we defined the changes in IRF1 and IRF7
mRNA in WT and SK1− /− pMEF following DENV infection. Basal
levels of IRF1 mRNA were significantly lower in uninfected SK1− /− in
comparison with uninfected WT cells, while mRNA levels of IRF7
were very low but not significantly different between the two
uninfected cell types (Figure 2d). Following DENV infection, IRF1
and IRF7 mRNA levels increased in both WT and SK1− /− cells.
mRNA levels, however, were significantly lower for both IRF1 and
IRF7 in SK1− /− compared with WT pMEF (Figure 2d). Together,
these results demonstrate similar responses of IFNAR1 protein and
Figure 2 Poor induction of Y701-p-STAT1, IRF1 and IRF7 in SK1− /− pMEF following DENV infection. WT and SK1− /− pMEFs were infected with DENV and
at the indicated time point pi culture supernatant, total cellular protein and RNA were harvested. (a) infectious virus release was quantitated from cell culture
supernatant by plaque assay. Results are shown from n=2 WT and SK1− /− pMEF isolates and representative of n=6 independent pMEF isolations and
infection experiments; (b) total protein was subjected to SDS-PAGE and western blot. Filters were serially probed for Y701-pSTAT1, total STAT1 and actin.
Bound proteins were detected by chemiluminescence and images collected with a LAS-4000. Results from a single experiment are shown; (b) western blots
from replicated experiments in two independent pMEF preparations and DENV infections were normalised and quantitated using Image J. Results represent
av± s.d., n=2. (c) Total RNA was extracted and subjected to RT-PCR for IRF1 and IRF7. Results were normalised against cellular cyclophilin and relative
RNA level determined by ΔCt method. Data represent av± s.e.m. from n=2 RT-PCR values from n=3 independent pMEF preparations and infection
experiments. *Po0.05, Student's unpaired t-test.
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IFNAR2 mRNA in WT and SK1− /− pMEF, lower IRF1 in SK1− /−
pMEF and a defect in induction of p-STAT1, IRF1 and IRF7 mRNA
following DENV infection in SK1− /− pMEF.
IFN-β-stimulated responses are altered in cells lacking SK1
We have previously observed that DENV-infected SK1− /− pMEFs
produce IFN-β, yet have reduced ability to induce ISG mRNAs,30 and,
as shown above, a reduced ability to induce p-STAT1 and IRF1 and -7
mRNA. To define the capacity of IFN to directly stimulate responses
in SK1− /− pMEF, we treated cells with IFN-β and assessed induction
of three key antiviral ISGs, IFIT1, viperin and CXCL10, by RT-PCR,
IFNAR signalling via p-STAT1 by western blot as well as IRF1 and
IRF7 mRNA by RT-PCR. Mock-treated WT and SK1− /− pMEF had
low but similar levels of IFIT1, viperin and CXCL10 mRNA
(Figure 3a). As expected, stimulation of cells with IFN-β resulted in
increased mRNA levels for all genes in both WT and SK1− /− pMEF.
Induction of viperin and IFIT1 mRNA by IFN-β was, however,
attenuated in SK1− /− compared with WT cells (Figure 3a). In contrast,
stimulation of cells with IFN-β induced comparable levels of CXCL10
mRNA in both WT and SK1− /− cells (Figure 3a). In addition, IFN-β
stimulation of cells produced a clear induction of pSTAT1 in WT cells,
a response that was markedly reduced in SK1− /− cells (Figure 3b). As
suggested in Figures 2b and c, basal levels of total STAT1 appeared
lower in SK1− /− compared with WT pMEF (Figure 3b). The total
STAT1 signal was low and varied between pMEF preparation and,
thus, further quantitation of changes in total STAT1 was not reliable to
pursue using western blot. Consistent with results in Figure 2d, IRF1
mRNA is reduced in mock-treated SK1− /− cells (Figure 3c). Further,
consistent with viperin and IFIT1 responses, stimulation of cells with
IFN-β resulted in poor induction of IRF1 in SK1− /− compared with
WT cells (Figure 3c). In contrast, but consistent with CXCL10
responses, stimulation of cells with IFN-β induced comparable levels
of IRF7 mRNA in both SK1− /− and WT cells (Figure 3c). This
suggests that IFN-β induction of IFIT1, viperin, IRF1 and pSTAT1
protein is influenced by SK1, while IFN-β induction of CXCL10 and
IRF7 is SK1-independent. These differential responses to DENV
infection and IFN-β stimulation are summarised in Figure 4a.
SK1− /− pMEFs have normal morphology but reduced levels of
cell-surface IFNAR1 and IRF1
As shown above, uninfected SK1− /− pMEFs have reduced IRF1
mRNA compared with WT cells (Figures 2c and 3c), suggesting the
potential for adaptive changes in DENV-induced and IFN-stimulated
responses in SK1− /− pMEF. We further compared uninfected WT and
SK1− /− pMEF. α-Tubulin staining of uninfected cells validated similar
cell morphology in WT and SK1− /− pMEF (Figure 5a). Comparison of
IFNAR1 on uninfected cells by flow cytometry, as shown in Figure 1,
demonstrates a modest but reproducible and significant reduction in
cell-surface IFNAR1 in uninfected SK1− /− compared with WT pMEF
(Figures 5b and c). These additional changes in uninfected SK1− /−
cells are summarised in Figure 4a.
Acute inhibition of SK1 does not affect components of the
IFN-stimulated pathways
Our prior studies have demonstrated reduced DENV induction of
ISGs in HEK293 cells treated with the SK1-I.30 This, however, is
accompanied by a reduced DENV infection, and thus this system is
not useful to discriminate effects on ISGs that are due to reduced SK1
activity compared with reduced induction by DENV replication per se.
We thus assessed whether the adaptive changes observed above in
Figure 3 IFN-β induction of IFN-stimulated pathways is reduced in SK1− /− pMEF. WT and SK1− /− pMEFs were stimulated with IFN-β (200 pg/ml). (a) At
8 h post stimulation, total RNA was harvested and subjected to RT-PCR for viperin, IFIT1 and CXCL10. Results were normalised against cellular cyclophilin
and relative RNA level determined by ΔCt method. Data represent av± s.e.m. from n=2 RT-PCR values from n=2 independent pMEF preparations and
stimulation experiments. *Po0.05, Student's unpaired t-test. (b) After 15–20 min IFN-β stimulation total protein was harvested and subjected to SDS-PAGE
and western blot. Filters were serially probed for Y701-pSTAT1, total STAT1 and actin. Bound proteins were detected by chemiluminescence and images
collected with a LAS-4000. Representative western blots are shown from experiments replicated in an independent pMEF preparation (n=2). (c) Total RNA
was extracted and subjected to RT-PCR for IRF1 and IRF7, and results presented are as described in a.
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Figure 4 Comparison of changes in protein and mRNAs in WT and SK1− /− pMEF following DENV infection or IFN-β stimulation. (a) Relative to WT pMEF:
blue, unchanged; green, induced; yellow, induced but significantly lower; red, reduced; ND, not determined; *, inconclusive. (b) Summary of changes in
basal, uninfected SK1− /− pMEF; (c) proposed pathways following DENV infection of SK1− /− pMEF.
Figure 5 Uninfected SK1− /− pMEFs have lower levels of IFNAR1 but normal cell morphology. (a) Uninfected WT and SK1− /− pMEFs were fixed and
immunostained with α-tubulin with secondary detection using Alexa-555. Nuclei were stained with Hoechst and images collected by confocal microscopy.
Representative images are shown. (b) Cells were harvested by scraping and stained using APC-conjugated IFNAR1 or isotype control antibodies, fixed and
subjected to flow cytometery. Representative histograms are shown, with the minor change in MFI indicated by a vertical line; (c) as in b with av± s.e.m. of
MFI from replicate flow analysis from n=2 independent pMEF preparations. Results from b, c are from the same experiments shown in Figure 1. Data
represent av± s.e.m. from n=3 values. *Po0.05, Student's unpaired t-test.
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uninfected SK1− /− pMEF (reduced IRF1 mRNA and ability to induce
p-STAT1) that are associated with the phenotype of enhanced DENV
infection and reduced IFN-stimulated responses were paralleled by a
chemical reduction in SK1. HEK293 cells were pretreated for 90 min
with SK1-I, RNA extracted and quantitated by RT-PCR. Results show
no change in basal levels of IRF1 mRNA (Figure 6a). Further, IFN-α
stimulation of SK1-I-treated HEK293 showed no major difference in
the ability to induce p-STAT1 (Figure 6a). As an alternative method to
reduce both SK1 activity and protein in human cells, we generated
HEK293 cells with doxycycline (DOX)-inducible expression of a SK1
shRNA that is linked to red florescent protein expression. SK1 activity
in these cells is significantly reduced by ~ 20%, likely due to leakiness
of the promoter driving the SK1 shRNA (Figure 6b). In addition,
overnight DOX treatment of these cells induced red florescent protein
and a further significant reduction in SK1 activity (Figure 6b). RNA
was extracted from uninfected cells and subjected to RT-PCR for
IRF1. Consistent with results of SK1-I treatment, SK1 shRNA
expression did not induce any change in basal levels of IRF1 mRNA
(Figure 6c). In addition, SK1 shRNA-expressing cells were stimulated
with IFN-α for 20 min, cells lysed and pSTAT1 analysed by western
blot. Results demonstrate no difference in ability of IFN-α to induce
p-STAT1 in cells induced to express the SK1 shRNA (Figure 6c).
shRNA-expressing cells were also DENV-infected and at 24 h pi
supernatant collected and analysed for infectious virus release by
plaque assay. Of note, DOX treatment of control cells, or non-induced
SK1 shRNA cells showed reduced DENV infection. This is further
significantly reduced, approximately one log by DOX treatment in SK1
shRNA cells (Figure 6d). Thus, a chemical or shRNA-mediated
reduction in SK1 is not sufficient to reproduce the adaptive changes
in basal components of the IFN and pathogen recognition responses
that we observe in SK1− /− cells. Further, in contrast to the enhanced
infection seen in SK1− /− pMEF but consistent with SK1-I and SKi
treatment of cells,30 expression of SK1 shRNA is associated with
reduced DENV infection.
DISCUSSION
Following viral infection of a cell, there is a complex host antiviral
response, including directly stimulated responses and secondary
IFN-stimulated pathways. Here we have defined novel innate
responses following DENV infection, including upregulation of
mRNA for IRF1 and -7, upregulation of mRNA for IFNAR2 and
downregulation of cell-surface IFNAR1. Our data also show that a
genetic lack of SK1 can influence specific aspects of responses to
infection and type I IFN stimulation, extending the evidence that
implicates SK1 in the cellular response to DENV.20,30,31
Figure 6 Chemical or shRNA inhibition of SK1 does not affect basal IRF1 mRNA or IFN-β induction of p-STAT1 but SK1 shRNA expression reduces DENV
infection. (a) HEK293 cells were treated with SK1-I for 90 min, and then stimulated with or without IFN-α (500 U ml−1) and total RNA and protein
harvested. RNA was subjected to RT-PCR for IRF1 with normalisation against cellular cyclophilin and relative RNA level determined by ΔCt method. Data
represent av± s.e.m. from n=3 RT-PCR values from n=2 independent pMEF replicates. Protein was subjected to SDS-PAGE and western blot. Filters were
serially probed for Y701-pSTAT1 and actin. Bound proteins were detected by chemiluminescence and images collected with a LAS-4000. Results are shown
from a single experiment that was replicated (n=2). (b) Control or SK1 shRNA cells were treated with DOX for the time indicated. Cells were harvested,
lysed and SK1 activity quantitated. Activity was normalised against total protein and expressed relative to activity in control shRNA cells. Data represent
av± s.d. from n=2 values. * indicates significantly different to control 0-h post DOX, ** indicates significantly different to control or SK1 shRNA 0-h post
DOX, Po0.05, Student's t-test. (c) HEK293 cells containing a DOX-inducible SK1 shRNA were treated overnight with DOX and then stimulated with IFN-α
and IRF1 mRNA, and Y701-p-STAT1 measured as described in a; (d) HEK293 cells containing a DOX-inducible control or SK1 shRNA were treated
overnight with DOX, DENV-infected and supernatants harvested at 24 h pi and analysed by plaque assay. Results represent av± s.e.m. from n=4
assay values from n=2 independent infection experiments. * indicates significantly different to control-DOX, ** indicates significantly different to SK1
shRNA-DOX, Po0.05, Student's t-test.
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Our prior data have suggested poor induction of ISGs following
DENV infection in SK1− /− pMEF.30 We further show that following
IFN-β stimulation, viperin, IFIT1, p-STAT1 and IRF1 but not
CXCL10 or IRF7 induction is compromised in the absence of SK1.
This suggests a role for SK1 in type I IFN-stimulated JAK/STAT-
mediated activation of some ISGs, but additionally the involvement of
a SK1-dependent pathway not involving the JAK/STAT pathway for
induction of IRF7 and CXCL10 that is activated during a DENV
infection. On the basis of literature, we suggest that this pathway may
be via interleukin-1, known to be induced during DENV and
responsible for induction of CXCL10, via a pathway described to be
positively regulated by SK1.26 This is summarised in Figure 4b. In
contrast, the ability of IFN to induce p-STAT1 was not reduced in cells
acutely treated with an inhibitor of SK1 activity (SK1-I) or expressing
a SK1 shRNA. A longer treatment of cells with SK1-I was not
employed as this can reduce cell proliferation, which will confound
analysis. Given these caveats, we suggest that the defect in DENV and
IFN-β-stimulated responses in SK1− /− pMEF reflects a biological link
of the SK1 and type I IFN pathway that is likely mediated by secondary
adaptive responses to long-term loss of SK1 and disruption of the
SK/S1P homeostatic balance.
In support of this we demonstrate alterations in uninfected SK1− /−
cells that could influence type I IFN responses. SK1− /− pMEFs have
normal α-tubulin staining, demonstrating that the poor DENV and
IFN-β responses in SK1− /− cells are not due to gross morphological
abnormalities that may affect multiple signalling pathways. In fact, in
contrast to the poor induction of some ISGs in SK1− /− cells, mRNA
for IFNAR2 is induced normally and IFNAR1 protein undergoes
downregulation in response to DENV infection in a manner compar-
able to WT cells. This demonstrates that many of the DENV-induced
responses are normal in SK1− /− pMEF. The downregulation of
IFNAR1 protein we have demonstrated here following DENV infec-
tion has been previously reported for other flaviviruses32 and shown to
be due to NS5 antagonism of the host cell prolidase protein, which is
involved in transport of IFNAR1 to the cell surface.33 Stimulation of
cells with S1P, the product of SK1 action, reportedly leads to
internalisation of S1PR1, co-internalisation of IFNAR1 into endo-
somes and refractory responses to IFN-α.34 In addition to DENV-
mediated downregulation of IFNAR1, we have also observed a small
but significant reduction in the basal levels of IFNAR1 in uninfected
SK1− /− cells. We thus propose that S1PR1-mediated downregulation
of IFNAR1 may be a mechanism underlying the lower IFNAR1
and contributing to refractory responses of SK1− /− cells to DENV and
IFN-β seen in our study.
Since prior data from our laboratory demonstrated poor induction of
IRF7 in the absence of SK1 and elevated basal IRF7 in SK1− /−
immortalised MEF,30 in combination with the prior literature linking
CXCL10, IRF1 and SK1,26 we rationalised to assess IRF1 and -7 and we
have shown that DENV infection induces both IRF1 and -7 mRNA.
IRF7 is well described to be induced by RNA viruses and toll-like
receptor-3 stimulation, and we previously reported significant upregula-
tion of IRF7 in DENV-infected MEF by microarray analysis.30 IRF1 is
traditionally described to be induced by cGAS activation in response to
DNA viruses, and our observed induction of IRF1 during DENV
infection supports the growing data demonstrating the importance of
cGAS-stimulated gene expression during RNA virus infections.5,35,36
Further, our data demonstrate decreased basal IRF1 mRNA in SK1− /−
pMEF but not following chemical or shRNA inhibition of SK1. This
difference may relate to the reduced ability to affect the total cellular
pool of SK1 protein or IRF1 mRNA in the shorter time frame of
chemical or shRNA inhibition of SK1. SK1 has role in ubiquitination of
IRF126 and may stabilise basal protein levels, which with long-term lack
of SK1 protein and activity (as in SK1− /− cells) but not acute reduction
in SK1 (as in SK1-I or SK1 shRNA treatment) could potentially
feedback to change basal levels of IRF1. While the SK1 dependency of
IRF1 induction during DENV infection was reflected by IFN-β
stimulation, the SK1-dependent induction of IRF7 seen following DENV
infection was not. Similar to our arguments for CXCL10, this implies a
SK1-dependent response during DENV infection that is not via IFN-β
and acts to induce IRF7 as summarised in Figure 4b. Regulation of IRF7
transcription is reported to be primarily driven by the type I IFNs37 but
IRF7 has also been described to be induced following viral infection,
such as Sendai virus, by IFN-β-independent direct viral-stimulated
pathways.38 Potentially, SK1 may influence these direct IFN-β-indepen-
dent pathways, whereby RNA viruses stimulate IRF7.
IRF1 and -7 are ‘master regulators’ of the IFN response and are
involved in a positive feedback loop that regulates the transcription of
IFNs. We focused on IRFs and analysed predicted promoter elements
that could potentially have a role in discriminating the SK1 depen-
dency of responses of viperin, IFIT1 and CXCL10 (Table 1). All gene
promoters contained several common response elements and at least
one predicted element for IRF and NFκB. Viperin and IFIT1 both
contain multiple IFN-stimulated response elements, while CXCL10
did not, and thus this element correlates with SK1 and IFN-β
dependency. IFIT1 has a total of five, and CXCL10 a total of three
different IRF elements. IFIT1 and viperin contain an IRF7 promoter
element, while only IFIT1 and CXCL10 have an IRF1 element
(Table 1). However, type I IFN-independent induction of viperin,
that is driven by IRF1, has previously been described in the context of
Newcastle disease virus and vesicular stomatitis virus infection.39 As
viperin, IFIT1 and CXCL10 have promoter elements for IRF1 and/or
IRF7, it is likely that lower levels of these IRFs will contribute to the
later poor induction of these ISGs in the absence of SK1. Dissecting
the mechanisms by which SK1, IRF1 and IRF7 contribute to
transcription of viperin, IFIT1 and CXCL10 requires further experi-
mentation, but it is clear that functional deficits in SK1 that has an
impact on IRF induction will have major consequences for the cellular
IFN response to infection (Figure 4b). In addition, the described role
for SK1 in stimulating NFκB-driven gene expression would be
predicted to have a major impact on induction of CXCL10,
which contains four NFκB elements, following DENV infection but
not IFN-β stimulation, and this is consistent with our observations.
A key finding in our study is reduced p-STAT1, an indicator
of activation of the JAK/STAT pathway, in DENV-infected
or IFN-β-treated SK1− /− pMEF. S1P has been previously implicated
Table 1 Promoter analysis of major antiviral response elements in
human viperin, IFIT1 and CXCL10 genes was performed by
identification of promoter regions with ‘Promoser’ and potential
transcription factor-binding sites using MatInspector
(Genomatix Suite)
Promoter element;
Gene name
ISRE IRF NFkB
1 2 3 7 8
Viperin 2 – – – 1 – 1
IFIT1 3 1 2 1 1 – 1
CXCL10 – 1 1 – – 1 4
Abbreviations: IRF, interferon regulatory factor; ISRE, interferon-stimulated response element;
NFkB, nuclear factor κB.
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in the JAK/STAT pathway, where a reduction in S1P through over-
expression of S1P lyase resulted in elevated p-STAT1 and inhibition
of IAV infection.28 Conversely, IAV infection of cells overexpressing
SK1 leads to reduced p-STAT1 and enhanced IAV infection.28 Our
experimental system differs with respect to the IAV infection model of
Seo et al.,28 with different viral stimuli and the added complexity of
DENV-mediated downregulation of IFNAR1. Both experimental sys-
tems represent extremes of SK1 activity with ~ 500-fold overexpression
of SK128,40 compared with our genetic lack of SK1. The SK1/S1P axis is
subject to strong autoregulation,41 and both the findings of Seo et al.,28
and our contrasting results, showing reduced type 1 IFN responses with
high and low SK1 levels, respectively, could be reconciled by S1PR1-
mediated downregulation of IFNAR134 leading to reduced ability to
induce p-STAT1. Our demonstration of a small but significant
reduction in IFNAR1 in SK1− /− cells shows that this does occur in
our system, although the molecular pathways by which the lack of SK1
leads to reduction in S1PR1 and downregulation of IFNAR1 in SK1− /−
pMEF remain to be defined. Further, we have also demonstrated
reduced basal IRF1 in SK1− /− pMEF. Together, these changes in
IFNAR1 and IRF1 would be predicted to place SK1− /− cells in a basal
state where pathogen recognition and stimulation of IFNAR signalling,
leading to p-STAT1 and transcription of ISGs, may be compromised
(Figure 4b). These effects of SK1− /− on IRF1 and p-STAT1 are not
observed in cells chemically treated or expressing a shRNA to induce a
short-term reduction in SK1, supporting the idea that these are adaptive
changes as a result of chronic reduction in SK1. Overall, these adaptive
changes and subsequent defects in DENV-induced and IFN-β-stimu-
lated pathways in SK1− /− pMEF correlate with our previously defined
enhanced DENV infection. In contrast, SK1-I or SK1 shRNA treatment
that is not associated with these adaptive changes is associated with
inhibition of DENV infection, reconciling the differences in DENV
susceptibility seen in these different systems for manipulating SK1.
In summary, our results implicate SK1 as a new factor that can
influence the susceptibility to DENV infection and induction of
antiviral and type I IFN-stimulated responses. The effect of SK1 on
these cellular functions is dependent on the context of the changes in
SK1, which is likely related to the close homeostatic regulation of the
SK/S1P axis. In some contexts the reduction in SK1 can be antiviral
without loss of innate responses to infection. This suggests the
potential to discriminate antiviral and IFN-stimulated response by
changes in the SK1/S1P axis, which, given the growing availability of
pharmaceuticals to modulate the SK1/S1P axis,42,43 becomes an
attractive option to consider. The contrasts in our outcomes between
different systems for manipulating SK1 however highlight the com-
plexity of these interactions and herald caution in extrapolating
outcomes from genetic lack of SK1 to effects of chemical or
shRNA-mediated inhibition of SK1.
MATERIALS AND METHODS
Cell culture
pMEFs were generated from six different WT and SK1− /− embryos and frozen
stocks generated at passage 3. Mice were used in accordance with animal ethics
181/12 approved by the SA Pathology/CALHN animal ethics committee. All
MEF cultures were used in infection studies within 2 weeks of thawing.
Individual studies were verified in at least two different pMEF cultures. Cells
were treated in culture for 15–20 min with recombinant mouse IFN-β
(Biolegend, San Diego, CA, USA) or pretreated for 90 min with 5 μM SK1-I
(Enzo Life Sciences, Farmingdale, NY, USA) prior to stimulation with IFN-β.
HEK293 cells expressing control or SK1 shRNA were generated following
lentivirus transduction and selection as previously described.44 Cells were
passaged in tetracycline-free media (Dulbecco's modified Eagles medium
(DMEM) with 10% (v/v) fetal calf serum) to minimise basal shRNA expression.
DENV infections and plaque assay
Cells were infected at a multiplicity of infection of 1 for 90 min and utilised
Mon601, a full-length DNA clone of the DENV type-2 (DENV-2) strain New
Guinea C,45 produced as described previously.46
Reverse transcription real-time polymerase chain reaction
Total RNA was extracted from cells using Trizol (Gibco, Gaithersburg, MD,
USA) DNase-treated and subjected to reverse transcription (RT) using random
hexamers (NEB, Ipswich, MA, USA). Complementary DNA was subjected to
real-time polymerase chain reaction (PCR) using primers and quantitation
methods as described previously.30 Additional primers, not described in Clarke
et al.,30 were used for mouse (m)-IFNAR2 (forward [f] GGATGGC
AGTGACAGTGAC; reverse [r] ATGGAGAACCCTCAGAAACAC), m-IRF1 (f-C
AGAGGAAAGAGAGAAAGTCC; r-CACACGGTGACAGTGCTGG). RT-PCR
included n=2 assay replicates and n=2–3 biological repeats in independent
pMEF isolates. Reactions included internal standards; results were normalised
against cylcophilin and relative RNA level determined by ΔCt method.
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis and
western blotting
Cells were lysed in extraction buffer (50 mM Tris pH 7.4, 150 mM NaCl, 2 mM
Na3VO4, 10 mM NaF, 1 mM EDTA, 10% (v/v) glycerol, 0.05% (v/v) triton
X-100, 10 mM beta-glycerophosphate, 1 mM dithiothreitol) with protease
inhibitors (Roche Complete Mini, Roche, Hawthorn, VIC, Australia) and
protein levels quantitated (Bio-Rad protein assay, Gladesville, NSW, Australia).
Thirty micrograms of total protein were subjected to sodium dodecyl sulphate-
polyacrylamide gel electrophoresis, proteins transferred to nitrocellulose
membranes and membranes serially incubated with antibodies for Y701
phosphorylated STAT1 (cat #9167, Cell Signaling Technology, Danvers, MA,
USA), total STAT1 (cat #9172, Cell Signaling Technology) and actin (anti actin,
clone C4 cat #MAB1501R, Millipore, Temecula, CA, USA). Bound antibody
complexes were detected by horseradish peroxidase-conjugated secondary
antibodies with detection by chemiluminescence (Clarity ECL substrate, Bio-
Rad) and collection of image with LAS-4000. Images were quantitated using
Image J (https://imagej.nih.gov/ij/).
Immunofluorescent staining for α-tubulin
Uninfected WT and SK1− /− pMEF were seeded on gelatin-coated glass coverslips,
cultured and fixed in 4% (w/v) paraformaldehyde in phosphate-buffered saline.
Fixed cells were washed, permeabilised in 0.05% (v/v) IGEPAL (Sigma, St Louis,
MO, USA) in phosphate-buffered saline, stained with α-tubulin with detection
using a secondary anti-mouse IgG-Alexa-555 (Molecular Probes, Eugene, OR,
USA) and nuclear staining with 5 μg ml− 1 Hoechst (Molecular Probes). Images
were captured by confocal fluorescent microscopy (Leica SP5, Nussloch,
Germany). Immunostaining was repeated on n=2 independent pMEF isolations.
Flow analysis of IFNAR1
Cells were cultured, left uninfected or DENV-infected, as described above. At
24 h post infection, cells were harvested, blocked in phosphate-buffered saline
with 3% (w/v) bovine serum albumin and immunostained with control IgG
(APC Mouse IgG1, cat 3400119, BioLegend) or anti-IFNAR1 (allophycocyanin
(APC) anti-mouse IFNAR1, cat #127313, BioLegend)-conjugated antibody.
Stained cells were fixed and subjected to flow cytometry (Accuri, BD systems,
Franklin Lakes, NJ, USA). Staining was performed in triplicate and repeated on
n= 2 independent pMEF isolations.
SK1 activity assays
Cells were lysed in extraction buffer and total protein quantitated, as described
above for sodium dodecyl sulphate-polyacrylamide gel electrophoresis analysis.
SK1 activity assay was quantitated by 32P transfer to sphingosine in vitro, as
described previously.47
Promoter analysis of IFIT, viperin and CXCL10
Promoter sequences 1000 bp upstream, and 50 bp downstream from the
transcription start site, were obtained for each gene using Promoser.
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Potential transcription factor-binding sites were identified using MatInspector
(Genomatix Suite, Muchen, Germany).
Statistics and data analysis
All experiments were performed at a minimum of duplicate samples with a
minimum of n= 2 biological replicates or as stated in figure legends. Statistical
differences were determined by Student's unpaired t-test with a Po0.05.
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